search

Active clinical trials for "Neuralgia"

Results 581-590 of 1062

Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic...

Neuropathic Pain

The purpose of this study is to find out if Exalgo (r) is beneficial for the patients with neuropathic pain.

Completed12 enrollment criteria

Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients...

Post Herpetic Neuralgia

The purpose of the study is to explore the safety and efficacy of a new once a day pregabalin formulation versus placebo for patients with post herpetic neuralgia (Shingles)

Completed7 enrollment criteria

Surface Acoustic Wave Ultrasound in Trigeminal Neuralgia Pain

Trigeminal NeuralgiaTic Douloureux

The "Suicide Disease", Trigeminal Neuralgia (TN) is arguably caused by one of the most discrete and eloquently reversible central nervous system lesions known to the field of neurology. Recently Dr Adahan H. and Dr Binshtok A. have completed an open label series of 25 subjects with refractory TN showing a remarkable positive response rate to TN's treatment with Low Intensity Low Frequency Surface Acoustic Wave Ultrasound (LILF/SAWU). The primary objective of this study, therefore, is to determine whether this apparent efficacy of Low Intensity Low Frequency Ultrasound (LILFU) in the treatment of TN pain could withstand the rigors of an n=1 crossover placebo control study. Participants with refractory trigeminal neuralgia pain despite optimized pharmacotherapy for at least six months will be screened for participation in the study based on rigorous inclusion and exclusion criteria. It is judged rather unlikely that such subjects will experience spontaneous regression of their disease in the course of this study. Patients meeting the inclusion criteria will be treated with four weeks of a placebo Low Intensity Low Frequency Surface Acoustic Wave Ultrasound (LILF/SAWU) device while continuing with their pharmaco-analgesic regimen. All patients will be crossed over to active LILF/SAWU therapy for the next four weeks. Patients will be blinded to all treatments throughout the study. Patients will be instructed to use the device daily overnight, and remove it upon wakening. The device is programmed to work in cycles of 30 minutes on and 30 minutes off, for a total of six- eight hours of intermittent treatment. At the end of the second month of the study, patients will be offered a choice as to whether they wished to continue with the current (active) device or go back to the 1st (sham) device. Patient's pain severity will be tracked every two weeks over the course of three months. Functional health and well being will be monitored at intake, post "Placebo" period, post "Active" period and at completion of the study.

Completed11 enrollment criteria

The InsuPad in Daily Life Study - Effect of Local Heating on Postprandial Glucose Excursions Using...

Type 1 Diabetes Mellitus With Diabetic Neuralgia

A randomised, controlled, cross-over study with inpatient and outpatient phases. The inpatient phase length will be two days, which include a "Control" day without activating the InSuPad and a "Test" day where the InsuPad is activated. The outpatient phase length is 8 weeks: 4 weeks without the device-"Control", and 4 weeks with the device-"Test".

Completed18 enrollment criteria

Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch

or Peripheral Nerve Injury (PNI)Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN)

The Summary of product characteristics (SmPC) for QUTENZA advises that topical anaesthetic is applied prior to the application of QUTENZA. This is a multi-center, randomized, assessor-blinded study which will investigate the use of an oral analgesic as an alternative form of pre-treatment for QUTENZA.

Completed6 enrollment criteria

Gabapentin Versus Transdermal Fentanyl Matrix for Chronic Neuropathic Pain

Neuropathic PainSpinal Stenosis

Gabapentin is a first line medication and fentanyl is second line medication in neuropathic pain. But, there is no head to head study on the efficacy of those medication in neuropathic pain. The hypothesis of this study is that the efficacy of the transdermal fentanyl matrix is not inferior to the gabapentin in neuropathic pain.

Completed17 enrollment criteria

Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic...

Peripheral NeuropathyNeuropathic Pain

The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving the pain associated with diabetic peripheral neuropathy (DPN) compared with placebo and duloxetine (a marketed drug approved for the treatment of painful DPN). The pain symptoms of DPN are thought to be due to damage to nerves caused by the diabetes.

Completed25 enrollment criteria

A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)

NeuralgiaPostherpetic

The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).

Completed30 enrollment criteria

Comparison of 2 Vials of Components of a Synthetic Geranium Oil

Neuropathic Pain

The purpose of this study is to determine which component of an artificial geranium oil helps to reduce your neuropathy pain.

Completed2 enrollment criteria

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

Postherpetic Neuralgia

The purpose of the study is to evaluate the efficacy of retigabine vs. placebo in reducing pain associated with post-herpetic neuralgia.

Completed10 enrollment criteria
1...585960...107

Need Help? Contact our team!


We'll reach out to this number within 24 hrs